伐地考昔
伐地考昔结构式
|
常用名 | 伐地考昔 | 英文名 | Valdecoxib |
|---|---|---|---|---|
| CAS号 | 181695-72-7 | 分子量 | 314.359 | |
| 密度 | 1.3±0.1 g/cm3 | 沸点 | 481.2±55.0 °C at 760 mmHg | |
| 分子式 | C16H14N2O3S | 熔点 | 162-164ºC | |
| MSDS | 中文版 美版 | 闪点 | 244.8±31.5 °C | |
| 符号 |
GHS08, GHS09 |
信号词 | Warning |
|
NFAT2 regulates COX-2 expression and modulates the integrin repertoire in endothelial cells at the crossroads of angiogenesis and inflammation.
Exp. Cell Res. 324(2) , 124-36, (2014) The mechanisms controlling the switch between the pro-angiogenic and pro-inflammatory states of endothelial cells are still poorly understood. In this paper, we show that: (a) COX-2 expression induced by VEGF-A is NFAT2-dependent; and (b) the integrin profile... |
|
|
Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1.
Oncotarget 6 , 39342-56, (2015) The antitumorigenic mechanism of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib is still a matter of debate. Using lung cancer cell lines (A549, H460) and metastatic cells derived from a lung cancer patient, the present study investigates the impa... |
|
|
Selective determination of COXIBs in environmental water samples by mixed-mode solid phase extraction and liquid chromatography quadrupole time-of-flight mass spectrometry.
J. Chromatogr. A. 1420 , 35-45, (2015) The development and performance evaluation of a method for the simultaneous determination of six pharmaceuticals belonging to the class of non-steroidal anti-inflammatory drugs (NSAIDs) which present high selectivity for the cyclooxygenase (COX)-2 isoform of ... |
|
|
Inhibition of cyclooxygenase-2 prevents intra-abdominal adhesions by decreasing activity of peritoneal fibroblasts.
Drug Des. Devel. Ther. 9 , 3083-98, (2015) Postoperative intra-abdominal adhesions are common complications after abdominal surgery. The exact molecular mechanisms that are responsible for these complications remain unclear, and there are no effective methods for preventing adhesion formation or refor... |